Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
about
Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohortAspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in SwedenStatins and breast cancer prognosis: evidence and opportunities.Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production.Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC)Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin useComorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study.Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.Racial differences in the effects of comorbidity on breast cancer-specific survival.Synergistic drug combinations from electronic health records and gene expression.De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancerEffects of breast cancer on chronic disease medication adherence among older women.Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties.Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia.Is digoxin a breast cancer risk factor?
P2860
Q28533813-997189CB-21E9-4EF1-9AB9-FC2AC0BAA3F1Q30828481-58C1276D-2F52-47A2-A6D1-59D2E2FE8661Q34206487-71066E10-875B-4D9C-8D5D-AAD05D271A96Q34408525-31035F01-EE55-4C97-B486-5F0BCA70B770Q35900009-58E18B05-CBD9-4785-9A14-F8687E1171FEQ35911581-71C725E6-E92C-4F15-AA92-BF4D03C23372Q36932703-0F7C5A1C-C764-4A4C-A60B-B1AEBB7325EAQ37017213-8952D8B8-A6D7-4240-B6BD-E4EA8F502468Q38673155-1FC78862-CABF-4A65-97D5-678D55220D4DQ38712771-27668977-9F1F-4DA0-A05D-316E8EDD3645Q39111678-43AB068E-D3DE-4EF1-86F5-49D06E71331AQ39534421-D8B7507B-41AC-4BAC-BDAB-629E7CB22986Q39998222-85C9D72A-CF9C-4057-A960-D6C385171EDAQ40281513-BC3681D4-ACE4-49EA-ADBD-CC3C69C9EA0BQ40836898-B1476CA3-27C1-4ACD-B2CD-F804B639CB20Q48179013-5D090E57-4291-446F-BF05-8B83BE763B75Q53149725-78BDB336-51F0-4511-80B0-D8B049B9255FQ58181734-3ED77046-182A-4047-991F-6641FFC786BC
P2860
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Hiding in plain view: the pote ...... educe breast cancer mortality.
@ast
Hiding in plain view: the pote ...... educe breast cancer mortality.
@en
type
label
Hiding in plain view: the pote ...... educe breast cancer mortality.
@ast
Hiding in plain view: the pote ...... educe breast cancer mortality.
@en
prefLabel
Hiding in plain view: the pote ...... educe breast cancer mortality.
@ast
Hiding in plain view: the pote ...... educe breast cancer mortality.
@en
P2860
P921
P356
P1476
Hiding in plain view: the pote ...... educe breast cancer mortality.
@en
P2093
Wendy Y Chen
P2860
P2888
P356
10.1186/BCR3336
P577
2012-12-10T00:00:00Z
P5875
P6179
1034619496